Last reviewed · How we verify
TTX-030
At a glance
| Generic name | TTX-030 |
|---|---|
| Sponsor | Trishula Therapeutics, Inc. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- TTX-030 in Combination With Immunotherapy and/or Chemotherapy in Subjects With Advanced Cancers (PHASE1)
- TTX-030 Single Agent and in Combination With Immunotherapy or Chemotherapy for Patients With Advanced Cancers (PHASE1)
- Phase 2 Study of TTX-030 and Chemotherapy With or Without Budigalimab for 1L mPDAC Patients (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- TTX-030 CI brief — competitive landscape report
- TTX-030 updates RSS · CI watch RSS
- Trishula Therapeutics, Inc. portfolio CI